BAIRONG-W(06608.HK) will spend HKD 25.67 million to repurchase 2.05 million shares on Jan 7, 2026 .
MAO GEPING COSMETICS CO., LTD. (01318.HK) announced that it has signed a strategic cooperation framework agreement with L Catterton, a world-leading consumer investment institution. The two parties intend to carry out cooperation in aspects including global market expansion, equity investment, capital optimization, and talent introduction.
China International Capital Corporation Limited (03908.HK) announced that the first tranche of its 2026 publicly issued perpetual subordinated bonds targeting professional investors will be book-built on January 8, 2026. The issuance size shall not exceed RMB 3 billion, the bond is abbreviated as "26 CICC Y1", and the coupon rate inquiry range is set at 1.90%-2.90%.
Jiangsu Guofu Hydrogen Energy Equipment Co., Ltd. (02582.HK) announced that it has entered into a pre-purchase order agreement with its 14%-owned Australian associate company, LineHydrogen (Australia) Pty Ltd, for the Tasmania Hydrogen Energy Project in Australia. The agreement covers a variety of equipment and services such as electrolytic hydrogen production systems and hydrogen refueling stations.
FUDANZHANGJIANG announced that it has entered into an agreement with Ping An Bank to subscribe for a principal-guaranteed floating-income structured deposit product with RMB270 million of its own idle funds. The product has an 83-day term, a maximum annualized return rate of 2.13%, and is rated as medium-low risk. It aims to enhance capital returns while complying with the company’s principles of capital safety and liquidity.
Eurasia Aerosol, a subsidiary of Precious PRECIOUS DRAGON, has entered into a construction agreement with a contractor to carry out the construction and renovation project of its production factory in Guangzhou, with a total investment of RMB34.8 million (approximately HK$38.3 million). Expected to be completed by July 29, 2026, the project will help the company expand production capacity, meet the requirements of environmental regulations, and enhance the competitiveness of its Original Brand Manufacturing (OBM) business.
SHANXI INSTALL announced that its proposed issuance of domestic corporate bonds has obtained the registration approval from the China Securities Regulatory Commission (CSRC). The approval permits the company to publicly issue corporate bonds with a total par value not exceeding RMB1.35 billion to professional investors, with a validity period of 24 months for the approval, during which the company may issue the bonds in installments.
QHD PORT announced that its total throughput in 2025 reached 432.53 million tons, a year-on-year (YoY) increase of 4.48% compared with 414.00 million tons in 2024. The throughput of the company's three major ports all achieved YoY growth, among which Huanghua Port led with a growth rate of 8.04%, while Qinhuangdao Port and Caofeidian Port recorded growth rates of 3.81% and 2.74% respectively.
After obtaining the general mandate from the shareholders' general meeting on November 26, 2025, GF SECannounced on January 6, 2026 that it intends to place 219 million new H-shares at HK$18.15 per share and issue HK$2.15 billion zero-coupon convertible bonds due 2027 with an initial conversion price of HK$19.82 per share. The total funds raised from the two items are expected to be approximately HK$6.113 billion, and the net proceeds are intended to be fully used for capital increase to overseas subsidiaries to support the development of international business. The placed shares account for approximately 12.87% of the existing H-shares. If the convertible bonds are fully converted, approximately 108 million H-shares can be issued, accounting for approximately 6.37% of the existing H-shares. The completion of both issuances is subject to the fulfillment of conditions such as listing approval and filing with the China Securities Regulatory Commission.
HUTCHMED announced that the Phase III stage of the ESLIM-02 study on its Syk inhibitor sostarlimab for the treatment of warm antibody autoimmune hemolytic anemia has met the primary endpoint, namely sustained hemoglobin response during the treatment period from Week 5 to Week 24. The study targets patients who relapsed or were refractory after previous standard treatments. The company plans to submit a new drug application for this indication to the National Medical Products Administration in the first half of 2026. The Phase III study of sostarlimab for the treatment of immune thrombocytopenia has also achieved positive results, and the company similarly plans to resubmit a new drug application for this indication in the first half of 2026.
APEX ACE HLDG (6036), through its indirectly wholly-owned subsidiary Avite International, paid a premium of US$3.5 million (approximately HK$27.3 million) to HSBC Life on January 5, 2026 to purchase a whole life insurance policy for Mr. Li, the executive director and chairman. This key person insurance policy constitutes a discloseable transaction under the listing rules. On the same day, the borrower confirmed its acceptance of a HK$215.8 million revolving trade loan facility provided by HSBC. The financing terms stipulate that if Mr. Li ceases to serve as chairman and chief executive officer, it will constitute a default. The board of directors believes that the policy can provide financial protection for the Group, and the death benefit may be higher than the premium expenditure in the future.
J&T Express (1519) announced its operating data for the fourth quarter and the full year of 2025. The annual package volume reached 30.129 billion, an increase of 22.2% year-on-year. Among them, the Southeast Asian market grew by 67.8% to 7.659 billion, and the new market grew by 43.6% to 404 million. The total package volume in the fourth quarter was 8.461 billion, an increase of 14.5% year-on-year. As of the end of 2025, the number of outlets in Southeast Asia increased to 10,800, and the number of trunk vehicles increased to 5,800. The company plans to hold a conference call on January 7, 2026, and the relevant data is unaudited.
Beijing Saimo Technology (2571) announced that it will introduce investors to inject RMB12.0098 million into its subsidiary Zhejiang Saimo in exchange for 49% equity, reducing its stake to 51% while maintaining consolidation. The valuation is approximately RMB12.116 million using the asset-based approach. The transaction constitutes a discloseable transaction under Listing Rules, with the cash portion to be used for R&D and no gain or loss expected to be recognized.
Weimob Inc. (02013.HK) announced that its subsidiary has signed a strategic cooperation agreement with Taobao Flash Sale, the local lifestyle service platform under Alibaba Group. The two parties will carry out cooperation in scenarios such as instant retail ecosystem co-construction, member integration, AI and data operations, facilitating Weimob’s clients to operate on the Taobao Flash Sale platform and expanding the business space of merchant solutions.
Yuexiu Property Company Limited (00123.HK) announced that on January 6, 2026, its subsidiary (in which it holds a 95% stake) successfully won a residential land parcel in Pudong New Area, Shanghai, with a bid price of RMB 2.561 billion. The land parcel covers an area of approximately 26,931.62 square meters, with a gross floor area (GFA) of about 67,329.05 square meters.
HISENSE HA disclosed that three of its subsidiaries have jointly subscribed to multiple wealth management products issued by COFCO Trust with a total of RMB1.855 billion of the group’s idle own funds between July 16, 2025, and January 6, 2026. All products are medium-to-low risk fixed-income instruments, investing in debt assets such as deposits and bonds. The move aims to improve capital utilization efficiency without affecting the company’s daily operations or core business development.
